Roche and Trimeris, Inc. have selected two next-generation fusion inhibitor peptides for co-development and progression into further preclinical studies as part of an ongoing collaboration in the development and commercialization of fusion inhibitors for the treatment of HIV/AIDS. The peptides, TR-291144 and TR-290999, first synthesized at Trimeris, are distinct compounds derived from HR2 sequences of HIV. In connection with this event, Trimeris will receive a payment from Roche. TR-291144 ...